Share

September 2017; 4 (5) ArticleOpen Access

High-dose cyclophosphamide without stem cell rescue in immune-mediated necrotizing myopathies

Christopher A. Mecoli, Arash H. Lahouti, Robert A. Brodsky, Andrew L. Mammen, Lisa Christopher-Stine
First published July 11, 2017, DOI: https://doi.org/10.1212/NXI.0000000000000381
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
921

Share

This article has a correction. Please see:

Article Information

vol. 4 no. 5 e381
DOI: 
https://doi.org/10.1212/NXI.0000000000000381
PubMed: 
28975138
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received February 10, 2017
  • Accepted in final form May 30, 2017
  • First Published July 11, 2017.
Copyright & Usage: 
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Christopher A. Mecoli, MD, MHS,
    2. Arash H. Lahouti, MD,
    3. Robert A. Brodsky, MD,
    4. Andrew L. Mammen, MD, PhD and
    5. Lisa Christopher-Stine, MD, MPH
  1. Christopher A. Mecoli, MD, MHS,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Arash H. Lahouti, MD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Robert A. Brodsky, MD,
    4. Scientific Advisory Boards:

    1. Alexion, Achillion, apellis

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Alexion

    Editorial Boards:

    1. Blood, editorial board

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Alexion

    Research Support, Government Entities:

    1. NIH, NHLBI

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. AA/MDS foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Andrew L. Mammen, MD, PhD and
    5. Scientific Advisory Boards:

    1. aTYR pharmaceuticals advisory board Biogen advisory board

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Experimental Neurology, Editorial Board, 2013- Arthritis and Rheumatism, Editorial Board, 2014-

    Patents:

    1. I am a patent holder on a commercial test for anti-HMGCR antibodies that is licensed to INOVA diagnostics; I receive no financial compensation for this since moving to the NIH in 2014.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Andrew Mammen: (1) NIAMS/NIH, 1-ZIA-AR041203, Principle Investigator, 2014-present (2) NIAMS/NIH, 5-K08-AR054783, Principle Investigator, 2008-2012 Jennifer Mammen (wife of Andrew Mammen): (1) NIDDK/NIH, 5-K23-DK095954, Principle Investigator, 2014-present

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License fee payments, Technology or Inventions:

    1. I am a patent holder on a commercial test for anti-HMGCR antibodies that is licensed to INOVA diagnostics; I received financial compensation for this only prior to joining the NIH in 2014.

    Royalty Payments, Technology or Inventions:

    1. I am a patent holder on a commercial test for anti-HMGCR antibodies that is licensed to INOVA diagnostics; I received financial compensation for this only prior to joining the NIH in 2014.

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Lisa Christopher-Stine, MD, MPH
    6. Scientific Advisory Boards:

    1. (1)Novartis (2) Medimmune (3) Walgreen's/Optioncare (4) Mallinckrodt (5) Idera Pharmaceuticals (6) Octapharma (7) Corbus

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1)Novartis, honorarium (2) Medimmune, honorarium (3) Walgreen's/Optioncare, honorarium (4) Mallinckrodt, honorarium (5) Idera Pharmaceuticals, honorarium (6)Octapharma, honorarium

    Editorial Boards:

    1. NONE

    Patents:

    1. (1) Detection of HMGCoA reductase (HMGCR) Antibodies in Patient Sera (Inova Diagnostics)

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Mallinckrodt Pharamaceuticals

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) NuFactor (2) Option Care (3) IgG America (4) MedProRx (5) CSL Behring

    Research Support, Government Entities:

    1. (1) NHLBI ?Inflammation and Coronary Endothelial Function (HL120905) DSMB Chair (2) NHLBI ?Inflammatory pathogenesis of coronary atherosclerosis in HIV? (HL14023), DSMB Chair.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Donald B. and Dorothy L. Stabler Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. (1) Detection of HMGCoA reductase (HMGCR) Antibodies in Patient Sera, Royalties, 2012

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. (1) McAloon and Friedman, P.C. 2014,2015 (2) Shaub, Ahmuty, Citrin, and Spratt, LLP 2014 (expert witness) (3) The Chartwell Law Offices, LLP (expert witness) (4) PK Law (expert witness) (5) Bodie, Dolina, Hobbs, Friddell & Grenzer, P.C.(expert witness)

  1. From the Johns Hopkins University School of Medicine (C.A.M., A.H.L., R.A.B., A.L.M., L.C.-S.), Baltimore; and National Institute of Health (A.L.M.), Bethesda, MD.
  1. Correspondence to Dr. Christopher-Stine: lchrist4{at}jhmi.edu
View Full Text

Article usage

Article usage: July 2017 to April 2023

AbstractFullPdfSource
Jul 201717126023Highwire
Aug 20172121522Highwire
Sep 20172774439Highwire
Oct 201775824Highwire
Oct 2017113026pmc
Nov 20175024317Highwire
Nov 201741815pmc
Dec 2017192613Highwire
Jan 201817023Highwire
Feb 20182279Highwire
Mar 201833113Highwire
Apr 20182417Highwire
Apr 201891516pmc
May 20180408Highwire
Jun 20181365Highwire
Jun 201831115pmc
Jul 201804610Highwire
Aug 2018102310Highwire
Aug 201811820pmc
Sep 20183207Highwire
Oct 201832910Highwire
Nov 20183116Highwire
Dec 20184244Highwire
Jan 20191159Highwire
Feb 201961916Highwire
Mar 201911416Highwire
Apr 201913011Highwire
May 201972110Highwire
Jun 20195184Highwire
Jul 201962115Highwire
Aug 2019215012Highwire
Sep 20191179Highwire
Oct 201952814Highwire
Nov 201931013Highwire
Dec 201933211Highwire
Jan 20201710Highwire
Feb 202021517Highwire
Mar 202051114Highwire
Apr 2020097Highwire
May 202011312Highwire
Jun 2020248Highwire
Jul 202001110Highwire
Aug 2020057Highwire
Sep 20201149Highwire
Oct 20202179Highwire
Nov 202001112Highwire
Dec 20203174Highwire
Jan 202131112Highwire
Feb 202112013Highwire
Mar 202141717Highwire
Apr 20213133Highwire
May 20211124Highwire
Jun 20212205Highwire
Jul 20213117Highwire
Aug 20212238Highwire
Sep 202112216Highwire
Oct 202152542Highwire
Nov 202141615Highwire
Dec 20212188Highwire
Jan 20220173Highwire
Feb 202212012Highwire
Mar 202221711Highwire
Apr 20221237Highwire
May 202256218Highwire
Jun 20221811Highwire
Jul 20223183Highwire
Aug 202243414Highwire
Sep 202282915Highwire
Oct 2022103115Highwire
Nov 2022156420Highwire
Dec 202210427Highwire
Jan 202312467Highwire
Feb 2023143110Highwire
Mar 202320257Highwire
Apr 2023102810Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles